Cerapedics announced the first patient treated with PearlMatrix P-15 Peptide Enhanced Bone Graft following its recent FDA approval. PearlMatrix Bone Graft is a Class III drug/device combination product for lumbar fusion.
Of the more than 350 spinal bone grafts in the U.S. market, Cerapedics has two of only three spinal bone grafts that have successfully gone through the PMA process.
“This first surgery post-approval is a significant milestone for Cerapedics,” said Valeska Schroeder, Chief Executive Officer of Cerapedics. “Every single team member behind the development, approval, and distribution of PearlMatrix P-15 Peptide Enhanced Bone Graft worked tirelessly to get this unique drug-device into the hands of surgeons to help them safely and effectively treat their patients. We are proud of the innovation we bring to the market, and we look forward to seeing the positive impact of our devices.”
Cerapedics announced the first patient treated with PearlMatrix P-15 Peptide Enhanced Bone Graft following its recent FDA approval. PearlMatrix Bone Graft is a Class III drug/device combination product for lumbar fusion.
Of the more than 350 spinal bone grafts in the U.S. market, Cerapedics has two of only three spinal bone grafts that...
Cerapedics announced the first patient treated with PearlMatrix P-15 Peptide Enhanced Bone Graft following its recent FDA approval. PearlMatrix Bone Graft is a Class III drug/device combination product for lumbar fusion.
Of the more than 350 spinal bone grafts in the U.S. market, Cerapedics has two of only three spinal bone grafts that have successfully gone through the PMA process.
“This first surgery post-approval is a significant milestone for Cerapedics,” said Valeska Schroeder, Chief Executive Officer of Cerapedics. “Every single team member behind the development, approval, and distribution of PearlMatrix P-15 Peptide Enhanced Bone Graft worked tirelessly to get this unique drug-device into the hands of surgeons to help them safely and effectively treat their patients. We are proud of the innovation we bring to the market, and we look forward to seeing the positive impact of our devices.”
Copy to clipboard 
